Agree with biosectinvestor and Flipper. I think at some level we all knew that when the trial investigators chose to change their trial endpoints and to compare outcomes among their study drug patients to outcomes in an external control population, their decision would be subject to methodological scrutiny and criticism. And here it is.
My chief critique of the critique is how it totally neglects to mention the exceptionally benign side effect profile of murcidencel. Knowing how important this is to patients, it makes me wonder how often these authors actually treat patients.
Other than that, I agree with Flipper: It's Christmas. Time to give this a rest. Have a merry one, and a happy New Year to all my fellow shareholders.
-- OJ
News 
Market Data 
Discover 
AI
